XML 75 R56.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Intangible Assets (Narrative) (Details) - USD ($) |  | 12 Months Ended |
--- | --- | --- | ---
Oct. 29, 2013 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Feb. 28, 2014
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Other revenue, potential upfront payment related to product sales |  | $ 4,700,000 |  |  |
Additions to intangible assets |  | 2,556,465 | $ 3,101,565 | $ 7,462,080 |
Amortization of intangible assets |  | 1,989,264 | 1,596,689 | $ 896,156 |
Product and License Rights |  |  |  |  |
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Intangible assets, gross |  | 18,011,362 | 16,477,749 |  |
Patents |  |  |  |  |
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Intangible assets, gross |  | 8,236,719 | 8,194,264 |  |
Additions to intangible assets |  | $ 100,000 | 3,300,000 |  |
Product, Kristalose | Product and License Rights |  |  |  |  |
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Intangible assets, useful life |  | 15 years |  |  |
Product Rights Agreement, U.S. Commercialization Rights for Kristalose from Inalco Biochemicals, Inc. and Inalco S.p.A. | Product, Kristalose | Product and License Rights |  |  |  |  |
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Product rights agreement, quarterly payments, expiration date |  | 7 years |  |  |
Quarterly payments made |  | $ 1,500,000 | $ 1,300,000 |  |
Product, Vaprisol | Product and License Rights |  |  |  |  |
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Intangible assets, gross |  |  |  |  | $ 3,000,000
Pernix Therapeutics | Collaborative Arrangement, Amended International Agreement |  |  |  |  |
Acquired Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Other revenue, potential upfront payment related to product sales | $ 4,000,000 |  |  |  |

X
- Definition Product rights agreement, quarterly payments, expiration date + References No definition available. + Details
Name: | cpix_ProductRightsAgreementQuarterlyPaymentsExpirationDate
Namespace Prefix: | cpix_
Data Type: | us-types:durationStringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Product Rights Agreement, Quarterly Payments Made + References No definition available. + Details
Name: | cpix_ProductRightsAgreementQuarterlyPaymentsMade
Namespace Prefix: | cpix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue Recognition, Potential Upfront Payment Related to Product Sales + References No definition available. + Details
Name: | cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales
Namespace Prefix: | cpix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=cpix_KristaloseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cpix_ProductRightsAgreementUSCommercializationRightsForKristaloseFromInalcoBiochemicalsIncAndInalcoSPAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=cpix_VaprisolMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=cpix_PernixTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cpix_AmendedInternationalAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |